Overview

Tracking progress of patients with severe rheumatoid arthritis (RA) who are receiving biologic agents, to monitor safety and effectiveness over the long-term.

The society's RA register has been in operation for more than 20 years and is run by an expert team based in the Versus Arthritis Epidemiology Unit at the University of Manchester. The register monitors the safety and effectiveness of biologic treatments and captures information about adverse events.

Patients on the register are flagged with the NHS Information Centre, which notifies the register of anyone who develops cancer plus any deaths, with their cause.

Patients with similar disease activity on conventional disease-modifying anti-rheumatic drugs and recruited in a cohort since closed still provide comparison data. The register is on the NIHR CLRN portfolio database, so there is financial support for registering patients.

Now recruiting for:


Amgevita



Benepali



Cimzia



Enbrel



Erelzi



Flixabi



Hulio



Humira



Hyrimoz



Idacio



Imraldi



Inflectra



Jyseleca



Kevzara



Olumiant



Remsima



Remicade



Rinvoq



Rixathon



RoActemra



Ruxience



Yuflyma



Xeljanz





If you're an NHS clinician, health professional or research network staff with a recruitment query about a patient or the treatment cohorts in rheumatoid arthritis, please get in touch.

The British Society for Rheumatology and the University of Manchester are joint data controllers for the register

Visit study website

Submit an enquiry